Shots:

• The company has initiated a P-III clinical study to evaluate the efficacy and safety of BAT2506 vs Simponi in ~ 480 volunteers with PsA. Simponi is approved for moderately to severely active RA- active PsA- active AS & UC
• BAT2506 is the 3rd proposed biosimilar of the company to enter a global P-III study
• Bio-Thera is developing other proposed biosimilars- including a bevacizumab & tocilizumab biosimilar that have completed P-III trial and is also pursuing biosimilar versions of ustekinumab- mepolizumab and dupilumab

  | Ref: Business Wire | Image: Business Wire